Boehringer and Lilly’s CAROLINA cardiovascular outcome trial for Trajenta meets primary endpoint of non-inferiority compared to glimepiride Read more
Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials Read more
Novartis receives FDA approval for Egaten for the treatment of fascioliasis, a neglected tropical disease Read more
AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma Read more
FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897 Read more
FDA advisory committee votes on Zynquista (sotagliflozin) as treatment for adults with type 1 diabetes Read more